Posted in Collaborations, Orthopaedics / Rheumatology
Faran S.A. is pleased to announce its cooperation with the pharmaceutical company Atnhas in the field of Osteoporosis, which concerns the original pharmaceutical product Bonviva (Ibandronic Acid).
Bonviva is used to treat osteoporosis (a disease that makes bones brittle) in postmenopausal women at risk of fractures.
Ibandronic acid is a bisphosphonate with high activity, belonging to the group of nitrogen-containing bisphosphonates, which act selectively on bone tissue and specifically inhibit osteoclast activity, without direct action on bone formation. It does not interfere with the concentration of osteoclasts. In postmenopausal women, ibandronic acid results in a progressive net increase in bone mass and a reduced incidence of fractures by reducing the increased rate of bone catabolism towards premenopausal levels.